

Press Release

Zug, 24 June 2011

Shareholders' meeting approved all proposals by the Board of Directors by a very large majority

36 shareholders representing 40% of the share capital were present at today's ordinary shareholders' meeting and approved all of the proposals submitted by the Board of Directors by a very large majority.

The incumbent board members Prof. Heinz Riesenhuber (Vice-Chairman) and Dr. Eduard E. Holdener both were re-elected for a term of three years.

The shareholders' meeting approved the reduction of the share capital to CHF 588,000,000 by cancelling 400,000 registered shares with a par value of CHF 60 each. Following the corresponding entry in the Commercial Register, there will therefore be 9,800,000 registered shares with a par value of CHF 60 each outstanding.

The presentation shown at the shareholders' meeting is available via the HBM BioVentures website www.hmbioventures.com.

For further information, please contact Dr Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hmbioventures.com.

Brief profile of HBM BioVentures Ltd

HBM BioVentures is invested globally in some 30 mature companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The lead products of many companies in HBM BioVentures' portfolio are either at an advanced stage of development or already available on the market. The investment focus currently is on follow-on financings for private companies in the portfolio that offer high value-creation potential. HBM BioVentures is an interesting alternative to investments in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a OR Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures AG
Bundesplatz 1
CH-6300 Zug/ Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com